

# Agnieszka Pań,ucha-Poniewiera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2342173/publications.pdf>

Version: 2024-02-01

52  
papers

2,718  
citations

186265

28  
h-index

175258

52  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2065  
citing authors

#	ARTICLE	IF	CITATIONS
1	The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice. <i>Behavioural Brain Research</i> , 2022, 418, 113633.	2.2	28
2	Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism. <i>Pharmaceuticals</i> , 2022, 15, 125.	3.8	18
3	The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110239.	4.8	27
4	The influence of the duration of chronic unpredictable mild stress on the behavioural responses of C57BL/6J mice. <i>Behavioural Pharmacology</i> , 2020, 31, 574-582.	1.7	20
5	Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats. <i>Behavioural Pharmacology</i> , 2019, 30, 471-477.	1.7	22
6	The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug. <i>Pharmacological Reports</i> , 2018, 70, 837-846.	3.3	22
7	Negative Allosteric Modulators of mGlu7 Receptor as Putative Antipsychotic Drugs. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 316.	2.9	23
8	The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice. <i>Neuropharmacology</i> , 2018, 141, 214-222.	4.1	16
9	The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 155-161.	4.8	23
10	Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. <i>Neuropharmacology</i> , 2016, 111, 169-179.	4.1	31
11	Glutamate-Based Drug Discovery for Novel Antidepressants. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 873-883.	5.0	14
12	Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. <i>Psychopharmacology</i> , 2016, 233, 2901-2914.	3.1	37
13	Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc. <i>Neuropharmacology</i> , 2015, 99, 517-526.	4.1	40
14	A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action. <i>Neuropharmacology</i> , 2015, 97, 338-345.	4.1	26
15	Prolonged administration of antidepressant drugs leads to increased binding of [3H]MPEP to mGlu5 receptors. <i>Neuropharmacology</i> , 2014, 84, 46-51.	4.1	15
16	NMDA antagonists under investigation for the treatment of major depressive disorder. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1181-1192.	4.1	40
17	The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent. <i>Psychopharmacology</i> , 2014, 231, 97-107.	3.1	23
18	Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. <i>Neuropharmacology</i> , 2014, 82, 59-68.	4.1	40

#	ARTICLE	IF	CITATIONS
19	mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. <i>Neuropharmacology</i> , 2013, 66, 40-52.	4.1	105
20	Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu4 receptor. <i>Neuropharmacology</i> , 2013, 66, 225-235.	4.1	39
21	Is the mGlu5 receptor a possible target for new antidepressant drugs?. <i>Pharmacological Reports</i> , 2013, 65, 1506-1511.	3.3	27
22	A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats. <i>Behavioural Brain Research</i> , 2013, 238, 109-112.	2.2	24
23	Investigational NMDA receptor modulators for depression. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 91-102.	4.1	44
24	On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice. <i>Neuropharmacology</i> , 2012, 62, 322-331.	4.1	21
25	Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 102-106.	4.8	23
26	A bright future of researching AMPA receptor agonists for depression treatment. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 583-585.	4.1	3
27	On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. <i>Psychopharmacology</i> , 2010, 212, 523-535.	3.1	51
28	The Antidepressant-Like Action of Metabotropic Glutamate 7 Receptor Agonist N,N $\epsilon$ -Bis(Diphenylmethyl)-1,2-Ethanediamine (AMN082) Is Serotonin-Dependent. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 1066-1074.	2.5	50
29	Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. <i>Neuropharmacology</i> , 2010, 59, 627-634.	4.1	53
30	The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. <i>Neuropharmacology</i> , 2009, 57, 227-234.	4.1	37
31	Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1454-1457.	4.8	10
32	Antidepressant-like activity of 8-Br-cAMP, a PKA activator, in the forced swim test. <i>Journal of Neural Transmission</i> , 2008, 115, 829-830.	2.8	13
33	Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. <i>Neuropharmacology</i> , 2008, 55, 517-524.	4.1	45
34	Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. <i>Brain Research</i> , 2007, 1184, 88-95.	2.2	29
35	Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. <i>Psychopharmacology</i> , 2007, 194, 555-562.	3.1	132
36	Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. <i>Amino Acids</i> , 2007, 32, 169-172.	2.7	54

#	ARTICLE	IF	CITATIONS
37	Are compounds acting at metabotropic glutamate receptors the answer to treating depression?. Expert Opinion on Investigational Drugs, 2006, 15, 1545-1553.	4.1	17
38	Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. British Journal of Pharmacology, 2006, 149, 581-590.	5.4	60
39	Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacology Biochemistry and Behavior, 2005, 81, 901-906.	2.9	122
40	The involvement of glutamate in the pathophysiology of depression. Drug News and Perspectives, 2005, 18, 262.	1.5	76
41	In the Amygdala Anxiolytic Action of mGlu5 Receptors Antagonist MPEP Involves Neuropeptide Y but not GABA <sub>A</sub> Signaling. Neuropsychopharmacology, 2004, 29, 514-521.	5.4	44
42	Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology, 2004, 46, 151-159.	4.1	125
43	Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Research Bulletin, 2003, 61, 159-164.	3.0	153
44	Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology, 2002, 42, 1016-1023.	4.1	51
45	Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology, 2002, 43, 181-187.	4.1	147
46	Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids, 2002, 23, 213-216.	2.7	61
47	Antidepressant-like properties of zinc in rodent forced swim test. Brain Research Bulletin, 2001, 55, 297-300.	3.0	137
48	Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology, 2001, 132, 1423-1430.	5.4	295
49	Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. British Journal of Pharmacology, 2001, 134, 807-814.	5.4	49
50	The effect of competitive and non-competitive NMDA receptor antagonists, ACPCand MK-801 on NPY and CRF-like immunoreactivity in the rat brain amygdala. Neuropeptides, 2001, 35, 219-226.	2.2	6
51	The effect of prolonged imipramine and electroconvulsive shock treatment on calcium/calmodulin-dependent protein kinase II in the hippocampus of rat brain. Neuropharmacology, 1999, 38, 597-603.	4.1	26
52	Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology, 1999, 38, 1831-1839.	4.1	123